https://www.selleckchem.com/products/gs-9973.html
PURPOSE Patients with diffuse large B-cell lymphoma (DLBCL) who fail to complete planned treatment with R-CHOP due to toxicity are sparsely described. We investigated the extent of failure to complete treatment (6 cycles or more, or 3 cycles + RT for patients with stage I disease) with R-CHOP for reasons unrelated to non-response, the determinants of such failure and the outcome among these patients. METHODS RESULTS 3149 adult DLBCL patients who started primary treatment with R-CHOP were identified through the Swedish lymphoma reg